AOD-9604 peptide vs tesamorelin explained: FDA status, fat-loss evidence, dosing, and safety. See which one has real human data and which is research-only.
AOD-9604 and tesamorelin are both peptides studied for fat reduction, but they work in completely different ways and have very different legal status in the United States. Tesamorelin is an FDA-approved prescription drug for excess visceral fat in adults with HIV-associated lipodystrophy, while AOD-9604 is a research-only growth hormone fragment that never received FDA approval for any human use. Neither is a general-purpose weight loss product, and anyone considering either should talk with a healthcare professional first.
What Is AOD-9604?
AOD-9604 is a synthetic peptide based on the tail end of human growth hormone, specifically amino acids 176 through 191 of the HGH molecule. Scientists trimmed HGH down to that fragment hoping to keep the fat-burning activity while removing the effects on blood sugar and tissue growth.
In cell and animal studies, AOD-9604 stimulates lipolysis, the breakdown of stored fat, and appears to limit new fat storage. The early human data were far less dramatic.
A Phase III obesity trial sponsored by the developer failed to meet its primary weight-loss endpoint, and the obesity program was abandoned. AOD-9604 is now sold as a research chemical and is banned in sport by WADA under category S0, which covers non-approved substances.
What Is Tesamorelin?
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), sold under the brand names Egrifta and Egrifta WR. It binds GHRH receptors in the pituitary gland and increases the body's own growth hormone release, which raises IGF-1 levels and shifts metabolism toward fat use.
The FDA approved tesamorelin in 2010 to reduce excess visceral adipose tissue in HIV-positive adults with lipodystrophy. It is not approved for general weight loss, and it is not approved for people who do not have HIV.
Standard dosing is one subcutaneous injection per day, either 2 mg or 1.4 mg depending on the formulation, and treatment requires a prescription and ongoing medical monitoring.
AOD-9604 vs Tesamorelin: Side-by-Side Comparison
| Feature | AOD-9604 | Tesamorelin |
|---|---|---|
| Peptide class | HGH fragment 176-191 | GHRH analog |
| How it works | Acts directly on fat cells to trigger lipolysis | Stimulates pituitary growth hormone release, raising IGF-1 |
| FDA approval | None, for any human use | Approved in 2010 for HIV-associated lipodystrophy (visceral fat) |
| Human evidence | Mixed; Phase III obesity trial failed | Randomized trials show reduced visceral adipose tissue |
| Typical use | Research chemical only | Prescription, once-daily subcutaneous injection |
| Common side effects | Injection site irritation; long-term safety data limited | Injection site reactions, joint and muscle pain, swelling, higher IGF-1, blood sugar changes |
| Sport status | WADA prohibited (S0) | WADA prohibited (S2, peptide hormones) |
Most aod 9604 vs tesamorelin discussions treat the two as competing fat burners, but that framing hides the biggest difference: only one of them is an approved medicine backed by large randomized trials.
Which One Has Better Evidence for Fat Loss?
Tesamorelin has the stronger evidence base by a wide margin. Multiple randomized controlled trials in adults with HIV-associated lipodystrophy showed significant reductions in visceral adipose tissue over 26 to 52 weeks, and the FDA reviewed that data before granting approval.
AOD-9604's human evidence is much thinner. Early studies suggested some fat loss, but the largest trial did not separate meaningfully from placebo, which is why the obesity program ended.
It is also worth noting what tesamorelin does not do. It targets visceral fat specifically and does not produce the 15 to 20 percent total body weight loss seen with GLP-1 based medications.
Dosing, Side Effects, and Monitoring
Dosing and administration
- Tesamorelin: 1.4 mg or 2 mg injected subcutaneously once daily, by prescription only, with regular lab monitoring.
- AOD-9604: No approved human dose exists. Research protocols have used roughly 300 mcg to 500 mcg per day, but those are experimental amounts, not medical recommendations.
Side effects and safety monitoring
Tesamorelin's label lists injection site reactions, joint and muscle aches, fluid retention, and elevated IGF-1. Blood sugar changes are possible, and doctors typically monitor IGF-1 during treatment.
Because AOD-9604 was never approved, it has no formal safety profile. Small studies reported headache and injection site irritation, but long-term human safety data are essentially absent.
How They Compare With Other Peptides
The aod 9604 vs mots-c debate compares two research peptides that act through very different pathways. MOTS-c is a mitochondrial-derived peptide studied for metabolic regulation and insulin sensitivity, while AOD-9604 targets lipolysis directly. Neither is FDA-approved for human use.
Another frequent comparison is aod-9604 vs cjc-1295 ipamorelin, which pairs a GHRH analog with a ghrelin receptor agonist to raise growth hormone. That combination works upstream, much like tesamorelin, rather than acting on fat cells directly.
Stacking questions are common online, which is why searches such as aod 9604 mots c tesamorelin ipamorelin keep appearing. Combining unapproved peptides multiplies the unknowns without adding proven benefit.
Compared with newer incretin drugs, both peptides look modest. Retatrutide produced roughly 24 percent weight loss at 48 weeks in a Phase II trial, far beyond anything reported for AOD-9604 or tesamorelin.
Legality, Sourcing, and Safety
Tesamorelin is available only by prescription from a licensed pharmacy, and it should be obtained through a physician rather than a website. AOD-9604 is not approved for human use in the United States.
People who search buy aod-9604 peptide usually land on vendors selling vials labeled for research use only. Those products are not held to pharmaceutical manufacturing standards, and independent testing has repeatedly found mislabeled or contaminated peptides in this market.
Both compounds are prohibited in sport. AOD-9604 falls under WADA category S0, and tesamorelin is covered as a GHRH analog under category S2.
Anyone with a medical reason to reduce visceral fat should discuss approved options with a healthcare professional instead of self-treating with research peptides.
Key Takeaways
- Tesamorelin is FDA-approved to reduce visceral fat in HIV-associated lipodystrophy; AOD-9604 is not approved for any human use.
- Tesamorelin raises the body's own growth hormone release, while AOD-9604 acts directly on fat cells as an HGH fragment.
- Tesamorelin has randomized trial support; AOD-9604 failed its Phase III obesity endpoint.
- Neither peptide is a substitute for approved weight-loss medications or for medical care.
Frequently Asked Questions
Is AOD-9604 or tesamorelin better for weight loss?
Tesamorelin has the stronger evidence because randomized trials showed it reduces visceral fat in adults with HIV-associated lipodystrophy, and the FDA approved it for that use. AOD-9604 failed its Phase III obesity trial and is not approved for human use. Neither is a general weight-loss drug.
Who is tesamorelin actually approved for?
The FDA approved tesamorelin in 2010 for HIV-positive adults with excess visceral adipose tissue caused by lipodystrophy. It is a prescription injection given once daily under medical supervision. It is not approved for general weight loss or for people without HIV.
Can you legally buy AOD-9604 in the United States?
AOD-9604 is sold by vendors as a research chemical, but it is not FDA-approved for human use, so it cannot legally be sold as a dietary supplement or drug. Injecting a research peptide carries real risks from unknown purity and dosing. It is also banned in sport under WADA category S0.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.